·¢²¼Ê±¼ä : ÐÇÆÚÈý ÎÄÕÂÁõÒ«¹â - ¶à°ÐµãpCRISPRÔØÌ壨µ¥×ÓÒ¶ºÍË«×ÓÒ¶Ö²ÎïÓã©Ê¹Ó÷½·¨2015-4-14(new)(1)¸üÐÂÍê±Ï¿ªÊ¼ÔĶÁdd760fb486868762caaedd3383c4bb4cf7ecb71d
3 cassettes: Pps-GGL/Pgs-GG2, Pps-GG2/Pgs-GG3, Pps-GG3/Pgs-GGR;
À©ÔöÏàÓ¦µÄU#-T1-gRNA, U#-T2-gRNA, U#-T3-gRNA;
4 cassettes: Pps-GGL/Pgs-GG2, Pps-GG2/Pgs-GG3, Pps-GG3/Pgs-GG4, Pps-GG4/Pgs-GGR;
À©ÔöÏàÓ¦µÄU#-T1-gRNA, U#-T2-gRNA, U#-T3-gRNA, U#-T4-gRNA
5¸ö»òÒÔÉϰе㣺Èç´ËÀàÍÆ¡£
4.5°Ð±êsgRNA±í´ïºÐÓëpYLCRISPR/Cas9ÔØÌåµÄÁ¬½Ó·½·¨
±¾ÔØÌåϵͳ¿É²ÉÓÃGolden Gate cloning (Engler et al., 2008; 2009), Gibson assembly·½·¨(Gibson, et al., 2009, 2010) 2ÖÖ²ßÂÔ×é×°Cas9ÔØÌåºÍ¶à¸ögRNA±í´ïºÐƬ¶Î¡£
Golden Gate ligationÊÇÀûÓÃBsa I (type IIs restriction enzyme)µÄʶ±ðλµãºÍÇиîλµã²»ÖصþµÄÌØÐÔ£¬¿ÉÒÔÉè¼Æ³ö¶àÖÖ²»Í¬µÄÇÒ·Ç»ØÎĽṹµÄÕ³ÐÔÄ©¶Ë£¨256-16=240ÖÖ£¬¼õÈ¥µÄ16ÖÖÊÇ»ØÎĽṹ£»µÚ6-7Ò³µÄPCRÀ©ÔöÒýÎïʹÓÃÁË16ÖÖ£©¡£¶à¸öÒªÁ¬½ÓµÄƬ¶ÎÔÚÁ¬½Óµã¾ßÓÐÌØÒìµÄ»¥²¹Ä©¶Ë¿ÉÒÔÁ¬½Ó£¨Èçͼ6, 4¸ö±í´ïºÐΪÀý)£¬¶ø·ÇÁ¬½ÓµãµÄÄ©¶ËÖ®¼ä²»»¥²¹²»ÄÜÁ¬½Ó£¨Ïàͬĩ¶Ë·Ö×Ó¼äÒ²²»»¥²¹²»ÄÜÁ¬½Ó£©£¬Òò´ËÁ¬½Ó·´Ó¦ÊÇÏò×ÅÄ¿±êµ¥·½Ïò½øÐУ¬Ð§Âʺܸߡ£ÓÉÓÚOsU6a-LacZ (AtU3b-LacZ) ¸½ÓÐLacZ±ê¼Ç»ùÒò(198 bp)£¬¿ÉÔÚº¬ÓÐX-galµÄÅàÑø»ù²úÉúÀ¶É«¾ú°ßɸѡÑôÐÔ¿Ë¡¡£
SpeIBsaIMluIPB-LGolden Gate cloningT1ctcggagcOsU6a(B-L)LacZctgagactOsU6bT2aagattctOsU6cT3gactctgaOsU3T4MluI(B-R)cggtgccaPB-RBsaIFigure 6. Generation of a 4-target construct by Golden Gate cloning
×¢£ºÓÉÒýÎïPps-GGLµ¼ÈëÔØÌåµÄΨһSpe IλµãÊÇÌرðÁôµÄÒ»¸ö¡°ºóÃÅ¡±¡£ÆäÓÃ;ÊÇ£¬ÔÚ¹¹½¨ºÃÒ»×éÄ¿µÄ°ÐµãsgRNA
±í´ïºÐµÄÔØÌåµÄ»ù´¡ÉÏ£¬Èç¹ûÇé¿öÐèÒªÔÙÌí¼ÓµÚ¶þ×éÆäËü°ÐµãsgRNA±í´ïºÐ£¬¿ÉÒÔÓÃSpe I½«ÔØÌåÇгÉÏß×´£¬ÔÙÓÃGibson Assembly½«µÚ¶þ×é°ÐµãsgRNA±í´ïºÐ¿Ë¡½øÈ¥¡£Èç¹ûÁ¬½Ó½Ï¶à£¨4¸ö»òÒÔÉÏ£©µÄsgRNA±í´ïºÐµÄ
ЧÂʵͣ¨×ª»¯²»ÄÜ»ñµÃÑôÐÔ¿Ë¡£©£¬¾ÍÒÔÁ¬½Ó²úÎïΪģ°å£¬ÒÔÒýÎïPB-L/PB-R (¼ûTable S1)À©Ôö³öÁ¬½ÓµÄ¶à¸ö±í´ïºÐ£¬ÔÙ´ÎÓëpYLCRISPR/Cas9ÔØÌåøÇÐÁ¬½Ó¡£
5. ÔØÌå¹¹½¨²Ù×÷·½·¨£º
°ÐµãÉè¼Æ£¬½ÓÍ·ÒýÎïºÏ³É£¨sgRNA·½·¨2£©£¨sgRNA·½·¨1£©sgRNAÖÊÁ£ÏÈÇкóÁ¬sgRNAÖÊÁ£sgRNAÖÊÁ£BsaIøÇÐsgRNA±í´ïºÐÁ¬½ÓÎïÁ¬½ÓµÚÒ»ÂÖPCR(ÿÖÖ2·´Ó¦)À©Ôö²úÎï(»ìºÏ)Golden GateÒýÎïµÚ¶þÂÖPCRGibson AssemblyÒýÎïgRNA±í´ïºÐgRNA±í´ïºÐBsaI ÇÐpYLCRISPR/Cas9ÖÊÁ£Golden Gate Á¬½Ó£¨±ßÇбßÁ¬£©Gibson AssemblyÁ¬½Óת»¯ÑôÐÔ¾úÂä(À¶É«£©£¬PCRÈ·ÈÏ£¬MluIøÇУ¬²âÐòFigure 7. Working flowchart for preparation of multi-target CRISPR/Cas9 constructs
£¨1£©¾úÖֻºÍÖÊÁ£ÌáÈ¡ÖƱ¸£º½«pYLCRISPR/Cas9¾úÖÖ(TOP10F¡¯)ºÍCRISPR/sgRNA vectors¾úÖÖ(DH10B)
·Ö±ðÔÚº¬Óп¨ÄÇùËØ£¨25 ¦Ìg/ml£©ºÍ°±ÜÐÇàùËØ£¨50¦Ìg/ml£©Æ½°åÅàÑø»ù»®ÏßÅàÑø¹ýÒ¹£¬ÌôÈ¡µ¥¾úÂäÅàÑø1mlÖÖ×ÓÒº£¬ÔÙÀ©´óÅàÑøÓÃÓÚÌáÈ¡ÖÊÁ£¡£ÓÃ2-3U Bsa IÊÔÇÐ~150ngÖÊÁ£(10¦Ìl)£¬µçÓ¾¼ì²é£¨Î´ÇеÄ80ngÖÊÁ£Îª¶ÔÕÕ£©¡£ ×¢£º²»Òª½«±£´æµÄ¾úÖÖÖ±½Ó½ÓÖÖ£¡
¹Ø¼üµã£ºpYLCRISPR/Cas9ÔØÌå½Ï´ó£¨Ô¼15~16.5 kb£©£¬¿½±´Êý½ÏµÍ£¨pBR322¸´ÖÆ×Ó£©£¬ÓÃÖÊÁ£Ð¡ÐÍÖùÌáÈ¡
´¿»¯µÄ»ØÊÕÂʽϵͣ¬Òò´Ë×îºÃÓÃÊʺÏÓڽϴóÖÊÁ£ÌáÈ¡µÄ´óÖù´¿»¯ÊÔ¼ÁºÐ£¨ÈçTIANGEN¹«Ë¾EndoFree Maxi Plasmid Kit£©ÌáÈ¡´¿»¯£¨ÓÉÓÚÈܳöµÄÖÊÁ£DNA¿ÉÄܺ¬ÓвÐÁôµÄÏ´Òº³É·Ö¼´ÒÒ´¼£¬ÇÒÌå»ý´óŨ¶ÈµÍ£¬×îºÃÔÙ×öÒ»´Î±ê×¼µÄÒÒ´¼³Áµí²Ù×÷ÒÔÈ¥³ý²ÐÁôÒÒ´¼ºÍ¼õÉÙDNAÈÜÒºÌå»ý£©£¬»òÓÃÆÕͨ¼îÁѽⷨÌáÈ¡£¨Ó÷Ó/Âȷ³éÌá2´ÎºóÔÙÒÒ´¼³Áµí£©¡£ÈܽâÔÚTE£¨Ô¼0.5g/l£©±£´æ¡£È¡²¿·ÖÖÊÁ£Ï¡ÊͳÉÔ¼100 ng/lÀ䶳±£´æ£¬×÷Ϊ²½Ö裨10£©Ê¹Óá£
¹Ø¼üµã£ºÓÉÓÚ½ÓÏÂÀ´ÒªÓõ½µÄBsa IÊǺÜÈÝÒ×ʧ»îµÄø£¬ÓÐʱÐÂÂòµÄBsa IÒ²ÊÇʧ»îµÄ£¡ÔÚ½øÐÐÒÔϲ½ÖèÖ®
Ç°£¬Ïȼì²âBsa I»îÐÔ£ºÅäÖÆ10 ¦Ìl Bsa I·´Ó¦Òº£¬º¬ÓÐ5 U Bsa I, ~100 ng pYLgRNA-U#(»òÆäËüÓÐAmpR»ùÒòµÄÖÊÁ£)¡£37¡æ·´Ó¦15minºóµçÓ¾¼ì²é£¬ÒÔδÇеÄÏàͬÖÊÁ£Îª¶ÔÕÕ¡£pYLgRNA-U#µÄBsa IͼÆ×¼ûFigure 3¡£ÎªÁ˾¡¿ÉÄܱ£³Öø»îÐÔ£¬×îºÃ°ÑBsa I·Ö×°³É¼¸¹ÜÀ䶳±£´æ¡£NEB¹«Ë¾µÄBsa I-HF¾¹ý
ÐÞÊÎÒÔ½µµÍÐÇ»îÐÔ£¬ÍƼöʹÓÃNEB BsaI-HFºÍÅäÌ×µÄCutSmart Buffer¡£
? sgRNA±í´ïºÐ¹¹½¨·½·¨1:
£¨2£©°Ðµã½ÓÍ·ÖƱ¸£º½«½ÓÍ·ÒýÎïTEÈܽâ³É100 ¦ÌMĸҺ£¬¸÷È¡1 ¦Ìl¼ÓÈëµ½98 ¦Ìl 0.5x TE»ìºÏÏ¡Ê͵½1 ¦ÌM¡£
Ô¼90¡æ 30 s£¬ÒÆÖÁÊÒÎÂÀäÈ´Íê³ÉÍË»ð¡£
£¨3£©sgRNAÔØÌåøÇУºÈ¡pYLgRNA-OsU3/LacZµÈÖÊÁ£¸÷1 ¦Ìg£¬ÔÚ25 ¦Ìl·´Ó¦ÓÃ10 U Bsa IøÇÐ20min£¬À䶳±£´æ¡£
¹Ø¼üµã£º²»ÒªÓÃÌ«¶àøºÍÌ«³¤Ê±¼ä¹ý¶ÈøÇУ¡
£¨4£©sgRNA±í´ïºÐÁ¬½Ó·´Ó¦£ºÃ¸ÇйýµÄpYLgRNA-OsU3/LacZµÈÖÊÁ£Óë¸÷Ëù¶ÔÓ¦½ÓÍ·Á¬½Ó·´Ó¦£º ³É·Ö
10¡ÁT4 DNA ligase Buffer pYLsgRNA-U#ÖÊÁ£ ½ÓÍ·
T4 DNA ligase(Takara) ddH2O
¼ÓÈëÁ¿ 1 ¦Ìl 0.5 ¦Ìl 0.5¦Ìl 0.05 ¦Ìl
²¹×ãµ½ 10 ¦Ìl
ÖÕŨ¶È(Á¿) 1¡Á
10~20 ng 0.05 ¦ÌM ~18 U
ÊÒΣ¨20-28¡æ£©Á¬½ÓÔ¼10-15 min
¹Ø¼üµã£º¹ý¶àDNA ligaseºÍ¹ý³¤Ê±¼äÁ¬½Ó»á²úÉú½Ï¶àµÚ6Ò³ËùÊö²úÎïIV &V¡£
×¢£º²»Í¬¹«Ë¾µÄT4 DNA ligaseµ¥Î»µÄ¶¨ÒåºÍ±ê¶¨µ¥Î»²»Í¬£¬ÈçTakaraµÄ350U/¦Ìl£¬NEBµÄ400 U/¦Ìl£¬µ«¾ø¶Ô»îÐÔµ¥Î»/¦Ìl¶¼½Ó½ü£¬¼´Ã¿10~15 ¦Ìl·´Ó¦´óÖÂʹÓÃ0.05~0.1 ¦Ìlø¡£
ÉÏÊö²½Ö裨3£©£¬£¨4£©Ã¸ÇкÍÁ¬½Ó¶þ²½·´Ó¦¿ÉÓÃÒ»²½Ã¸ÇÐ-Á¬½Ó·´Ó¦£¨±ßÇбßÁ¬·¨£©Ìæ´ú£º
ÅäÖÆ10 ¦Ìl 1x Bsa IøÇÐÁ¬½Ó£¨Restriction-ligation£©·´Ó¦Òº£ºÔÚ1x Bsa I-øÇÐBufferÖмÓÈëATPÖÁÖÕŨ¶È0.5~1.0 mM£¨´Ëbuffer¶ÔBsa IºÍligase¶¼ÓÐЧ£©£¬¼ÓÈëÔ¼10~20 ng pYLgRNA-U#ÖÊÁ££¨Ô¤ÏÈÅäºÃ20 ng/¦Ìl±£´æ£©£¬0.5 ¦Ìl½ÓÍ·£¨×îÖÕŨ¶È0.05 ¦ÌM£©£¬3~5 U Bsa I£¬~15 U T4 DNA ligase¡£Èç¹ûʵÑéÊÒûÓÐATP£¬ÔÚ1xÄÚÇÐøBufferÖмÓÈë0.5-1.0 ¦Ìl 10 x NEB T4 DNA ligase buffer£¨10x NEB T4 DNA ligase bufferÖк¬ÓÐ10 mM ATP, µ«10x Takara T4 DNA ligase bufferÖк¬ÓÐ1.0 mM ATP£¬Òò´ËÓÅÏÈÓÃNEBµÄ£©¡£×¢Ò⣺ûÓмÓÄÚÇÐøbuffer¶øµ¥´¿¼ÓT4 DNA ligase bufferȱÉÙKCl»òNaCl£¬²»ÊʺÏBsa IøÇУ¡£©¡£ÓñäÎÂÑ»·ÒÇ£¨»òPCRÒÇ£©Ñ»··´Ó¦5Ñ»·£º37¡æ 5 min£¬20¡æ 5 min¡£
£¨5£©µÚÒ»ÂÖÀ©Ôö£ºÃ¿¸ösgRNA±í´ïºÐ·ÖΪ2¸öPCR·´Ó¦£¬¸÷15 ¦Ìl·´Ó¦Ìåϵ£ºÈ¡0.5 ¦ÌlÁ¬½Ó²úÎïΪģ°å£¬Ê¹ÓõÚ6Ò³ÒýÎïU-F/½ÓÍ··´ÏòÒýÎ·´Ó¦1£©£¬ºÍ½ÓÍ·ÕýÏòÒýÎï/gR-R£¨·´Ó¦2£©£¬¸÷0.2¦ÌM,ÊÊÁ¿¸ß±£ÕæPCRø¡£25-28Ñ»·£º94¡æ 10s£¬60¡æ 15s £¬68 ¡æ 20 s¡£(ÈÎÒâ) È¡4 ¦ÌlµçÓ¾¼ì²é£¨·´Ó¦2²úÎﳤ¶ÈÔ¼140 bp£¬ÓÃ2%ÇíÖ¬Ìǽº£©¡£Èç¹ûÀ©Ôö²úÎï½ÏÈõ£¬Ò²¿ÉÒÔ¼ÌÐøµÚ¶þÂÖPCR¡£
×¢£ºËäÈ»ÓõڶþÂÖPCRµÄλÖÃÌØÒìÒýÎïÖ±½Ó´ÓÁ¬½Ó²úÎïÒ²¿ÉÒÔÀ©Ôö³öÄ¿±ê²úÎµ«ÓÃ2ÂÖPCRÀ©Ôö¿ÉÒÔ¸üÎȶ¨µØµÃµ½ÌØÒìÐÔÄ¿±ê²úÎïÇÒÄܱÜÃâ¿ÕÔزúÎïÀ©Ôö£¬¼ûFigure 4¡£
¹Ø¼üµã£º×îºÃʹÓÃKOD-Plus (TOYOBO)£¬±£Õæ¶È×î¸ßÇÒÐԼ۱ȸߣ¬»òKOD FX¡£²»ÒªÊ¹ÓÃÄÜÔÚ²úÎï3¡¯¸½¼ÓA¼î»ùµÄDNA¾ÛºÏø£¬´ËA¼î»ùʹ²úÎïÔÚµÚ¶þÂÖPCRÖв»Ó뻥²¹Á´Åä¶Ô¶ø²»ÄÜÑÓÉ첹ƽ£©¡£
£¨6£©µÚ¶þÂÖPCR£º
°´¸½Â¼1ͨÓÃÒýÎïËùÊö£¬Ô¤ÏȽ«Î»ÖÃÌØÒìÒýÎï¶Ô»ìºÏ³É10¡Á¹¤×÷Òº£¬Ã¿ÖÖ1.5 ¦ÌM£º ÒýÎï×éºÏ
1¸ö°Ðµã£ºPT1R£»
2¸ö°Ðµã£ºPT1£¬PT2R£» 3¸ö°Ðµã£ºPT1£¬PT2£¬PT3R;
4¸ö°Ðµã£ºPT1£¬PT2£¬PT3£¬PT4R;
5¸ö°Ðµã£ºPT1£¬PT2£¬PT3£¬PT4£¬PT5R;
6¸ö°Ðµã£ºPT1£¬PT2£¬PT3£¬PT4£¬PT5£¬PT6R£»
7¸ö°Ðµã£ºPT1£¬PT2£¬PT3£¬PT4£¬PT5£¬PT6£¬PT7R£» 8¸ö°Ðµã£ºPT1£¬PT2£¬PT3£¬PT4£¬PT5£¬PT6£¬PT7£¬PT8R
È¡µÚÒ»ÂÖPCR²úÎï1 ¦ÌlÓÃH2OÏ¡ÊÍ10±¶£¬¸÷È¡1 ¦Ìl»ìºÏΪģ°å¡£¸÷±í´ïºÐ20-50 ¦Ìl PCR (1¸ö°Ðµã50 ¦Ìl£» 2-3¸ö°Ðµã¸÷30 ¦Ìl£»4¸ö»òÒÔÉϰеã¸÷20 ¦Ìl)¡£¼ÓÈë1/10Á¿Ã¿ÖÖÒýÎï×éºÏ¹¤×÷Òº£¨×îÖÕŨ¶È0.15 ¦ÌM£©¡£Ê¹ÓÃÊÊÁ¿KOD-Plus»òÆäËü¸ß±£ÕæPCRø¡£
À©Ôö17-20Ñ»·(ʵ¼ÊÇé¿öµ÷Õû)£º95 ¡æ 10s£¬58¡æ 15s£¬68 ¡æ20 s¡£ È¡2 -3 ¦ÌlµçÓ¾¼ì²é²úÎﳤ¶ÈÊÇ·ñ·ûºÏ£¨×¢1£©£¬²¢¹À¼ÆÑùÆ·µÄ´óÖÂŨ¶È¡£
×¢1£º¸÷ÖÖÆô¶¯×ÓgRNA±í´ïºÐµÄ³¤¶ÈΪ£¨À¨ºÅΪBsa IÇк󣩣º
µ¥×ÓÒ¶±í´ïºÐ
PCRÀ©Ôö²úÎﳤ¶È£¨bp£©
BsaIøÇк󳤳¤¶È£¨bp£©
Ë«×ÓÒ¶±í´ïºÐ
PCRÀ©Ôö²úÎﳤ¶È£¨bp£©
BsaIøÇк󳤶ȣ¨bp£©
LacZ-OsU6a-gRNA OsU6a-gRNA OsU6b-gRNA OsU6b-gRNA LacZ-OsU3-gRNA OsU3-gRNA
831 629 515 924 766 603
801 599 485 894 736 573
LacZ-AtU3d-gRNA AtU3d-gRNA LacZ-AtU3b-gRNA AtU3b-gRNA AtU6-1-gRNA AtU6-29-gRNA
486 284 709 507 487 502
456 254 679 477 457 472
£¨7£©¸ù¾Ý¸÷ÑùÆ·²úÎï¹ÀËãµÄÁ¿£¬°ÑËùÓвúÎï´óÖµÈÁ¿»ìºÏ£¬·Ó³éÌáÒÒ´¼³Áµí»òÓÃPCR²úÎï´¿»¯kit´¿»¯¡£ ¹Ø¼üµã£º´Ë²½ÖèÊÇΪÁ˳ýÈ¥DNA¾ÛºÏø£¬ÒÔ·ÀÖ¹ÏÂÃæ²½ÖèBsa IøÇвúÉúµÄÕ³ÐÔÄ©¶Ë±»²¹Æ½¡£
? sgRNA±í´ïºÐ¹¹½¨·½·¨2 (Overlapping PCR):
£¨8£©È¡2-5 ng pYLgRNA-OsU#ÖÊÁ£ÎªÄ£°å£¬ÔÚÒ»¸ö·´Ó¦ÖÐʹÓÃ4ÖÖÒýÎU-FºÍgRT#+ ¸÷0.2 ¦ÌM£¬U#T#-ºÍgRT#+£¨Table S1£©¸÷0.1 ¦ÌM¡£25-28 Ñ»·£º94 ¡æ 10s£¬58¡æ 15s £¬68 ¡æ 20 s¡£ ÔÚÀ©Ôö¹ý³ÌÖУ¬¿ªÍ·µÄÈô¸ÉÑ»·Ê±U-F/U#T#-À©³öU#--T#ÐòÁУ¬gR-R/gRT#+À©³öT#--sgRNAÐòÁС£ºóÆÚµÄÑ»·ÖÐͨ¹ýoverlapping PCR²úÉú2¸öƬ¶ÎºÏ²¢µÄsgRNA±í´ïºÐƬ¶Î¡£
(9) È¡µÚÒ»ÂÖPCR²úÎï1¦ÌlÓÃH2OÏ¡ÊÍ10±¶£¬È¡1 ¦ÌlΪģ°å£¬°´ÒÔÉϲ½Ö裨6£©½øÐеڶþÂÖPCR¡£
? ×é×°sgRNA±í´ïºÐµ½pYLCRISPR/Cas9ÔØÌå (²ßÂÔI, Golden Gate cloning)£º
(10) øÇÐ-Á¬½Ó·´Ó¦